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Chemistry. General protocols.
All reagents and solvents were purchased from commercial vendors and used as received. NMR spectra were recorded at 21 ºC on a For UPLC-MS: Identity was determined on a SQ mass spectrometer by electrospray ionization. Mobile Phase A consisted of either 0.1% ammonium hydroxide or 0.1% trifluoroacetic acid in water, while mobile Phase B consisted of the same additives in acetonitrile. The gradient ran from 5% to 95% mobile Phase B over 0.8 minutes at 0.45 mL/min. An Acquity BEH C18, 1.7 um, 1.0 x 50 mm column was used with column temperature maintained at 65°C. Compounds were dissolved in DMSO at a nominal concentration of 1 mg/mL, and 0.25 µL of this solution was injected.
General Protocol A.
A solution of phenylacetonitrile (1 equiv) and 2-bromo-or 2-chloropyridine (1.1 equiv) in dry DMF (0.15 M) was cooled to 0 °C. Potassium tert-butoxide (2.0 equiv) as a solution in DMF (0.8 M) was added dropwise. The reaction mixture was stirred for 3 h at 0 ºC and then warmed to rt over 30 min. The reaction was quenched with satd aq NH 4 Cl, extracted with ether, washed with water, dried over MgSO 4 , filtered and concentrated onto silica gel. The crude product was purified by flash chromatography using ethyl acetate in hexanes.
2-(4-Fluorophenyl)-2-(6-(trifluoromethyl)pyridin-2-yl) acetonitrile (4). The title compound was prepared using General Procedure A (43 mg, 69% 
2-(6-Chloropyridin-2-yl)-2-(4-fluorophenyl)aceto-nitrile (9).
The title compound was prepared using General Procedure A (17 mg, 20% 
2-(4-Chlorophenyl)-2-(5-chloropyridin-2-yl) acetonitrile (14

6-(Cyano(4-fluorophenyl)methyl)picolinonitrile (25). The title compound was prepared using
General Procedure A (19 mg, 23%). 
2-(6-Chloro-5-(trifluoromethyl)pyridin-2-yl)-2-(4-(trifluoromethyl)phenyl)acetonitrile (28).
The title compound was prepared using General Procedure A (56 mg, 44%). 1 
2-(4-Chloro-2-fluorophenyl)-2-(6-chloro-5-(trifluoro-methyl)pyridin-2-yl)acetonitrile (32).
The title compound was prepared using General Procedure A (70 mg, 57% 
2-(6-Chloro-5-(trifluoromethyl)pyridin-2-yl)-2-(2,4-dichlorophenyl)acetonitrile (36).
The title compound was prepared using General Procedure A (83 mg, 42%). gel. The crude product was purified by flash chromatography using ethyl acetate in hexanes.
2-(4-Chlorophenyl)pentanenitrile (37). The title compound was prepared using General
Procedure B (27 mg, 21% 
2-(4-Chlorophenyl)-4-(2-methoxyethoxy)butanenitrile (42
2-(4-Fluorophenyl)-4-methoxybutanenitrile (47). The title compound was prepared using
General Procedure B (54 mg, 38% 
2-(5-Fluoropyridin-2-yl)hexanenitrile (50). The title compound was prepared using General
Procedure B (99 mg, 70% 
2-(4-Chlorophenyl)-2-((2-methoxyethyl)amino) aceto-nitrile (44).
To a solution of sodium sulfite (210 mg, 1.6 mmol) and 1 N HCl (1.5 mL) in water (8.5 mL) was added 4-chlorobenzaldehyde (211 mg, 1.5 mmol). The reaction mixture was stirred for 15 minutes and 2-methoxyethanamine (0.14 ml, 1.6 mmol) was added. The reaction mixture was cooled over 45 min to 0 °C and 1 M aq sodium cyanide (3 mL) was added dropwise. The reaction mixture was stirred for 14 h gradually warming to room temperature. The reaction mixture was extracted with Et 2 O (4 mL x 3), dried (Na 2 SO 4 ), filtered and concentrated. The crude product was purified by silica flash chromatography with ethyl acetate and hexanes to deliver 44 (153 mg, 45% 
2-(4-Chlorophenyl)-2-(pyrrolidin-1-yl)acetonitrile (45
2-Chloro-6-((4-chlorophenyl)(1H-tetrazol-5-yl)-methyl)pyridine (52). A solution of 2-(4-
chlorophenyl
Production and Purification of PvdQ
P. aeruginosa PvdQ acylase protein was prepared as previously described by Drake. 1 Briefly, PvdQ was directed to the periplasm of E. coli BL21(DE3) and produced without a purification tag. 1,2 Through standard expression, the protein was processed via autoproteolytic cleavage to the mature α/β heterodimer. The periplasmic proteins were obtained via osmotic lysis with 0.5 M sucrose. PvdQ was then purified via sequential ammonium sulfate precipitation, anion exchange, and gel filtration chromatography. 1 PvdQ was stored in TNT buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, and 0.2 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP)).
Determination of the structure of PvdQ bound to 3 and 4.
Co-crystals of PvdQ with the inhibitors were grown at 20 °C by hanging drop vapor diffusion utilizing 10-15% PEG 4000, 50-100 mM RbCl, and 50 mM Hepes (pH 7.5) using 0.250 mM of each ligand. Ethylene glycol was used as a cryoprotectant. Data were collected remotely 3 for compound 3 at SSRL and for compound 4 with a Rigaku 007HF X-ray generator. Liganded complexes were determined using difference Fourier methods starting from the coordinates of structure 3L94 from the Protein Data Bank with ligand and water molecules removed from the starting model to avoid bias. Iterative model building and refinement were continued to completion for all liganded PvdQ structures using COOT 4 and refinement with PHENIX 5 and REFMAC. 6 Data collection and refinement statistics can be found in Table S1 of the supporting information. To validate target specificity prior to initiation of SAR studies, hit compound 3 was examined for effectiveness against P. aeruginosa in the presence and absence of EDDHA in minimal media. During growth in minimal media, even in the absence of the chelator, pyoverdine production still improves cell growth due to low iron concentrations. Therefore, we also examined the effect of the compound on a pvdQ mutant strain of P. aeruginosa. The results show that 3 is effective against cells in the presence or absence of the chelator, although more effective when 2 µM EDDHA is added and the requirement for pyoverdine production is enhanced. The compound shows no impact on the pvdQ mutant. 
Representative Biochemical Inhibition Assay
Subsequently, the final probe compound has been investigated in the biochemical and growth assays described in the text. Multiple assays were performed with different synthetic preparation of 4, giving minor differences in values largely due to the instability of the compounds described 
PAK Mutant Strain Construction
To construct the mexAB-oprM deletion, ∼1 kb chromosomal DNA segments flanking the targeted locus were PCR amplified from PAK chromosomal DNA by using specific oligonucleotide primers (Table S1 ) and were joined through splicing by overlap extension-PCR; 7 deletions were marked by inclusion of a unique HindIII restriction site in the overlapping (internal) primers. The resulting ∼2 kb DNA fragment was inserted into the KAN r Gateway entry vector pDONR201 (Gateway cloning system; Invitrogen, Carlsbad, CA) and transferred into the Gateway destination vector pEXGmGW 8 resulting in pEXGmGWD-ΔmexAB-oprM. This suicide plasmid was introduced into P. aeruginosa PAK by electroporation, selected for chromosomal insertion on LB agar containing gentamicin (100 µg/mL), and then counter-selected for loss of the plasmid backbone on LB agar containing 5% sucrose. 9 To confirm deletions, the region surrounding the target gene was PCR amplified from chromosomal DNA and digested with the HindIII to detect the unique marker. 
